Floridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway

Marine Drugs

Volumn 6, Issue 3, 2008, Pages 407-417

  Courtois, Anthony ^a,b   Simon Colin, Christelle ^a   Boisset, Claire ^a   Berthou, Christian ^b   Deslandes, Eric ^b   Guezennec, Jean ^a   Bordron, Anne ^b  

^a IFREMER   (France)

^b Universite de Brest   (France)

Author keywords

Alpha galactosyl glycerol; Complement system; Immunomodulation; Marine algae

Indexed keywords

ANTIGEN; EPITOPE; FLORIDOSIDE; GALILI EPITOPE; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; N ACETYLGLUCOSAMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL DESTRUCTION; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; DRUG ACTIVITY; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MASTOCARPUS STELLATUS; NONHUMAN; RED ALGA; STRUCTURAL HOMOLOGY; XENOGRAFT;

ALGAE; MASTOCARPUS STELLATUS; RHODOPHYTA;

EID: 53349172725     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md6030407     Document Type: Article

References (20)

1. 13C spectral assignment of floridoside. Carbohydr. Res. 2002, 337(3), 279-80.
2. Simon-Colin, C.; Michaud, F.; Leger, J. M.; Deslandes, E. Crystal structure and chirality of natural floridoside. Carbohydr. Res. 2003, 338(22), 2413-6.
3. Putman, E. W.; Hassid, W. Z. Structure of galactosylglycerol from Iridea laminaroides. Biochem. J. 1954, 79, 7-12.
4. Galili, U.; Shohet, S. B.; Kobrin, E.; Stults, C. L.; Macher, B. A. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J. Biol. Chem. 1988, 263(33), 17755-62.
5. Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 2001, 344(14), 1058-66.
6. Walport, M. J. Complement. Second of two parts. N. Engl. J. Med. 2001, 344(15), 1140-4.
7. Lutz, H. U.; Stammler, P.; Jelezarova, E.; Nater, M.; Spath, P. J. High doses of immunoglobulin G. attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996, 88(1), 184-93.
8. Brasher, G. W.; Hartley, T. F. Quantitation of IgA and IgM in umbilical cord serum of normal newborn infants. J. Pediatr. 1969, 74(5), 784-8.
9. Galili, U.; Basbaum, C. B.; Shohet, S. B.; Buehler, J.; Macher, B. A. Identification of erythrocyte Gal alpha 1-3Gal glycosphingolipids with a mouse monoclonal antibody, Gal-13. J. Biol. Chem. 1987, 262(10), 4683-8.
10. Thall, A.; Etienne-Decerf, J.; Winand, R. J.; Galili, U. The alpha-galactosyl epitope on human normal and autoimmune thyroid cells. Autoimmunity. 1991, 10(2), 81-7.
11. Galili, U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol. Cell. Biol. 2005, 83(6), 674-86.
12. Galili, U.; Rachmilewitz, E. A.; Peleg, A.; Flechner, I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J. Exp. Med. 1984, 160(5), 1519-31.
13. Galili, U.; Macher, B. A.; Buehler, J.; Shohet, S. B. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1→3)-linked galactose residues. J. Exp. Med. 1985, 162(2), 573-82.
14. Galili, U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol. Today 1993, 14(10), 480-2.
15. Rieben, R.; Bovin, N. V.; Korchagina, E. Y.; Oriol, R.; Nifant'ev, N. E.; Tsvetkov, D. E.; Daha, M.R.; Mohacsi, P. J.; Joziasse, D. H. Xenotransplantation: in vitro analysis of synthetic alpha-galactosyl inhibitors of human anti-Galalpha1→3Gal IgM and IgG antibodies. Glycobiol. 2000, 10(2), 141-8.
16. Morgan, B. P.; Harris, C. L. Complement therapeutics; history and current progress. Mol. Immunol. 2003, 40(2-4), 159-70.
17. Edens, R. E.; Linhardt, R. J.; Bell, C. S.; Weiler, J. M. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacol. 1994, 27(2), 145-53.
18. Trail, P. A.; Bianchi, A. B. Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 1999, 11(5), 584-8.
19. Kazatchkine, M.; Hauptmann, G.; Nydegger, U. Dosages hémolytiques des composants du Complément; Société française d'Immunologie: Paris, France, 1985; pp. 15-44.
20. Blondin, C.; Chaubet, F.; Nardella, A.; Sinquin, C.; Jozefonvicz, J. Relationships between chemical characteristics and anticomplementary activity of fucans. Biomaterials 1996, 17(6), 597-603.